Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fredy Suter

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Scandinavian Journal of Infectious Diseases. Supplementum|March 6, 2004
Genotypic resistance tests for the management of patients at simplification of highly active antiretroviral therapyFredy Suter, Florio Ghinelli
Le Infezioni in Medicina|July 9, 2010
Severe bacterial infections in haemodialysis patientsSebastiano Leone, Fredy Suter
Lancet (London, England)|September 12, 2006
The Trivacan studyFranco Maggiolo, Diego Ripamonti, Fredy Suter
AIDS (London, England)|April 26, 2007
Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected womanDiego Ripamonti, Franco Maggiolo, Fredy Suter
Lancet (London, England)|April 28, 2004
HIV-1 and hepatitis B virus: time for a re-think?Diego Ripamonti, Franco Maggiolo, Fredy Suter
The Journal of Antimicrobial Chemotherapy|April 26, 2005
Switch strategies in patients on effective HAARTFranco Maggiolo, Diego Ripamonti, Fredy Suter
HIV Clinical Trials|June 20, 2003
Once-a-day HAART: dream or reality?Franco Maggiolo, Diego Ripamonti, Fredy Suter
The Lancet. Infectious Diseases|August 28, 2022
Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agentsNorberto Perico, Monica Cortinovis, Fredy Suter, et al.
AIDS (London, England)|June 6, 2008
Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infectionDiego Ripamonti, Basilio Marini, Alessandro Rambaldi, et al.
AIDS (London, England)|December 13, 2001
Discordant immunological response in HIV-positive patients on non-nucleoside reverse transcriptase inhibitor-based regimensDiego Ripamonti, Claudio Arici, Franco Maggiolo, et al.
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Scandinavian Journal of Infectious Diseases. Supplementum|March 6, 2004
Genotypic resistance tests for the management of patients at simplification of highly active antiretroviral therapyFredy Suter, Florio Ghinelli
Le Infezioni in Medicina|July 9, 2010
Severe bacterial infections in haemodialysis patientsSebastiano Leone, Fredy Suter
Lancet (London, England)|September 12, 2006
The Trivacan studyFranco Maggiolo, Diego Ripamonti, Fredy Suter
AIDS (London, England)|April 26, 2007
Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected womanDiego Ripamonti, Franco Maggiolo, Fredy Suter
Lancet (London, England)|April 28, 2004
HIV-1 and hepatitis B virus: time for a re-think?Diego Ripamonti, Franco Maggiolo, Fredy Suter
The Journal of Antimicrobial Chemotherapy|April 26, 2005
Switch strategies in patients on effective HAARTFranco Maggiolo, Diego Ripamonti, Fredy Suter
HIV Clinical Trials|June 20, 2003
Once-a-day HAART: dream or reality?Franco Maggiolo, Diego Ripamonti, Fredy Suter
The Lancet. Infectious Diseases|August 28, 2022
Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agentsNorberto Perico, Monica Cortinovis, Fredy Suter, et al.
AIDS (London, England)|June 6, 2008
Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infectionDiego Ripamonti, Basilio Marini, Alessandro Rambaldi, et al.
AIDS (London, England)|December 13, 2001
Discordant immunological response in HIV-positive patients on non-nucleoside reverse transcriptase inhibitor-based regimensDiego Ripamonti, Claudio Arici, Franco Maggiolo, et al.
Pageof 6